Literature DB >> 21858676

Type I IFNs signaling and apoptosis resistance in glioblastoma cells.

Andrea Sgorbissa1, Andrea Tomasella, Harish Potu, Ivana Manini, Claudio Brancolini.   

Abstract

Deletion of type I IFN genes and resistance to apoptosis induced by type I IFNs are common in glioblastoma. Here we have investigated the importance of the constitutive weak IFN-signaling in the apoptotic response to IFN-α in glioblastoma cells. U87MG cells hold a deletion of type I IFN genes, whereas in T98G cells the spontaneous IFN signaling is intact. In response to IFN-α U87MG cells produce much less TRAIL, while other IFN-inducible genes were efficiently up-regulated. Alterations in TRAIL promoter sequence and activity were not observed. DNA methylation can influence TRAIL transcription but without overt differences between the two cell lines. We also discovered that TRAIL mRNA stability is influenced by IFN-α, but again no differences can be appreciated between the two cell lines. By silencing IFNAR1 we provide evidences that the spontaneous IFN signaling loop is required to sustain elevated levels of TRAIL expression, possibly through the regulation of IRF-1. Despite the presence/absence of the constitutive IFN signaling, both cell lines were resistant to IFN-α induced apoptosis. Targeting the deisgylase USP18 can overcome resistance to IFN-induced apoptosis only in T98G cells. Alterations in elements of the extrinsic apoptotic pathway, such as Bid and c-FLIP contribute to apoptotic resistance of U87MG cells. Down-regulation of USP18 expression together with the induction of ER-stress efficiently restored apoptosis in U87MG cells. Finally, we demonstrated that the BH3-only protein Noxa provides an important contribution in the apoptotic response to ER-stress in USP18 silenced cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21858676     DOI: 10.1007/s10495-011-0639-4

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  20 in total

1.  Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.

Authors:  Kleiton Silva Borges; Angel Maurício Castro-Gamero; Daniel Antunes Moreno; Vanessa da Silva Silveira; Maria Sol Brassesco; Rosane Gomes de Paula Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-09       Impact factor: 4.553

2.  The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis.

Authors:  Ivana Manini; Andrea Sgorbissa; Harish Potu; Andrea Tomasella; Claudio Brancolini
Journal:  Cancer Biol Ther       Date:  2013-09-19       Impact factor: 4.742

3.  Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.

Authors:  Marianela Candolfi; Gwendalyn D King; Kader Yagiz; James F Curtin; Yohei Mineharu; A K M Ghulam Muhammad; David Foulad; Kurt M Kroeger; Nick Barnett; Regis Josien; Pedro R Lowenstein; Maria G Castro
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

Review 4.  Interferons as inducers of apoptosis in malignant cells.

Authors:  Kevin P Kotredes; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

5.  Cell-type-specific innate immune response to oncolytic Newcastle disease virus.

Authors:  Moanaro Biswas; Sandeep R P Kumar; Adria Allen; Wang Yong; Ramadevi Nimmanapalli; Siba K Samal; Subbiah Elankumaran
Journal:  Viral Immunol       Date:  2012-07-18       Impact factor: 2.257

6.  Multifaceted activities of type I interferon are revealed by a receptor antagonist.

Authors:  Doron Levin; William M Schneider; Hans-Heinrich Hoffmann; Ganit Yarden; Alberto Giovanni Busetto; Ohad Manor; Nanaocha Sharma; Charles M Rice; Gideon Schreiber
Journal:  Sci Signal       Date:  2014-05-27       Impact factor: 8.192

Review 7.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Authors:  Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

8.  Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.

Authors:  Angel Mauricio Castro-Gamero; Kleiton Silva Borges; Daniel Antunes Moreno; Veridiana Kill Suazo; Mayara Missono Fujinami; Rosane de Paula Gomes Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

Review 9.  Vaccine therapies in malignant glioma.

Authors:  Taemin Oh; Eli T Sayegh; Shayan Fakurnejad; Daniel Oyon; Jonathan Balquiedra Lamano; Joseph David DiDomenico; Orin Bloch; Andrew T Parsa
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

10.  Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.

Authors:  Mahua Dey; Alan L Chang; Jason Miska; Derek A Wainwright; Atique U Ahmed; Irina V Balyasnikova; Peter Pytel; Yu Han; Alex Tobias; Lingjiao Zhang; Jian Qiao; Maciej S Lesniak
Journal:  J Immunol       Date:  2015-05-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.